SGMT · Sagimet Biosciences Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-14 | Kemble George |
Director, Executive Chairman |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. This option is fully vested and exercisable as of the date hereof. |
Stock Option (Right to Buy)
|
24,369 |
| 2026-08-14 | Kemble George |
Director, Executive Chairman |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
350,987 |
| 2026-08-14 | Kemble George |
Director, Executive Chairman |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. This option is fully vested and exercisable as of the date hereof. |
Stock Option (Right to Buy)
|
326,618 |
| 2026-08-14 | Kemble George |
Director, Executive Chairman |
Convert↑
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
Series A Common Stock
|
326,618 |
| 2026-08-14 | Kemble George |
Director, Executive Chairman |
Convert↑
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
Series A Common Stock
|
24,369 |
| 2026-08-11 | Kemble George |
Director, Executive Chairman |
Convert↑
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
Series A Common Stock
|
9,751 |
| 2026-08-11 | Kemble George |
Director, Executive Chairman |
Convert↑
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
Series A Common Stock
|
10,455 |
| 2026-08-11 | Kemble George |
Director, Executive Chairman |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. This option is fully vested and exercisable as of the date hereof. |
Stock Option (Right to Buy)
|
10,455 |
| 2026-08-11 | Kemble George |
Director, Executive Chairman |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
20,206 |
| 2026-08-11 | Kemble George |
Director, Executive Chairman |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. This option is fully vested and exercisable as of the date hereof. |
Stock Option (Right to Buy)
|
9,751 |
| 2026-07-20 | Happel David |
Director, President & CEO |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
64,051 |
| 2026-07-20 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
10,545 |
| 2026-07-20 | Kemble George |
Director, Executive Chairman |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
18,844 |
| 2026-06-12 | Hoelscher Paul W. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-06-12 | GRAMMER ELIZABETH A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-06-12 | Phillips Anne M. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-06-12 | Jarrett Jennifer |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-06-12 | Kemble George |
Director, Executive Chairman |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-06-12 | SEIDENBERG BETH C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
39,567 |
| 2026-05-28 | Chauche Thierry |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-05-28 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
100,000 |
| 2026-05-28 | Happel David |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
300,000 |
| 2026-05-28 | Grauer Andreas |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
35,000 |
| 2026-04-20 | Grauer Andreas |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying this option shall vest and become exercisable on April 20, 2027, with the remaining 75% vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
264,759 |
| 2026-02-19 | Martins Eduardo Bruno |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
88,000 |
| 2026-02-19 | Chauche Thierry |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
88,000 |
| 2026-02-19 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Award↑
Filing footnotes — Series A Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Series A Common Stock
|
44,000 |
| 2026-02-19 | Chauche Thierry |
Chief Financial Officer |
Award↑
Filing footnotes — Series A Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Series A Common Stock
|
44,000 |
| 2026-02-19 | Happel David |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
256,000 |
| 2026-02-19 | Martins Eduardo Bruno |
Chief Medical Officer |
Award↑
Filing footnotes — Series A Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Series A Common Stock
|
44,000 |
| 2026-02-19 | Happel David |
Director, President & CEO |
Award↑
Filing footnotes — Series A Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Series A Common Stock
|
128,000 |
| 2026-02-19 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
88,000 |
| 2026-02-10 | Happel David |
Director, President & CEO |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
12,101 |
| 2026-02-10 | Martins Eduardo Bruno |
Chief Medical Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
3,640 |
| 2026-02-10 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
2,622 |
| 2026-02-10 | Chauche Thierry |
Chief Financial Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
1,312 |
| 2025-11-20 | Kemble George |
Director, Executive Chairman |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Series A Common Stock
|
37,688 |
| 2025-11-04 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Award↑
Filing footnotes — Series A Common Stock (Direct)
Represents restricted stock units ("RSUs") granted in connection with the Reporting Person's promotion within the Company. Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Series A Common Stock
|
9,855 |
| 2025-11-04 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted in connection with the Reporting Person's promotion within the Company. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
13,367 |
| 2025-07-21 | Happel David |
Director, President & CEO |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
65,478 |
| 2025-07-21 | Rozek Elizabeth |
Chief Legal & Admin. Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
10,780 |
| 2025-07-21 | Martins Eduardo Bruno |
Chief Medical Officer |
Sell↓
Filing footnotes — Series A Common Stock (Direct)
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Series A Common Stock
|
8,277 |
| 2025-06-09 | Hoelscher Paul W. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
32,250 |
| 2025-06-09 | Jarrett Jennifer |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
27,268 |
| 2025-06-09 | Phillips Anne M. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
27,268 |
| 2025-06-09 | Kemble George |
Director, Executive Chairman |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
32,250 |
| 2025-06-09 | SEIDENBERG BETH C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
32,250 |
| 2025-06-09 | Walbert Timothy P |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
32,250 |
| 2025-06-09 | GRAMMER ELIZABETH A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
32,250 |
| 2025-06-06 | SEIDENBERG BETH C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 6, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
28,522 |